SPA
ANGO icon

Sherbrooke Park Advisers’s AngioDynamics ANGO Stock Holding History

Sherbrooke Park Advisers’s Portfolio ANGO Stock Details ANGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-37,263
Closed -$219K – 893
2024
Q1 		$219K Buy
+37,263
New +$221K 0.04% 692

Other funds holding ANGO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Sherbrooke Park Advisers's ANGO Position: Q2 2024 in Review

Sherbrooke Park Advisers sold out of AngioDynamics (ANGO) in Q2 2024, closing a stake of 37,263 shares — an estimated $219K sold.

Sherbrooke Park Advisers first reported a position in ANGO in Q1 2024 and held it in 1 quarter. The position peaked at $219K in Q1 2024. 139 funds tracked by Wall St. Rank hold ANGO as of Q2 2024.

  • Sherbrooke Park Advisers reported no remaining AngioDynamics position as of Q2 2024 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 37,263 AngioDynamics shares in Q2 2024, an estimated $219K.
  • Sherbrooke Park Advisers first reported a position in AngioDynamics in Q1 2024 and held it in 1 quarter.
  • Sherbrooke Park Advisers's AngioDynamics position peaked at $219K in Q1 2024.
  • 139 funds tracked by Wall St. Rank held AngioDynamics as of Q2 2024.

Based on Sherbrooke Park Advisers's 13F filing for Q2 2024, filed 14 Aug 2024.